<DOC>
	<DOC>NCT01442363</DOC>
	<brief_summary>This randomized, placebo-controlled, parallel, multi-center, double-blind pilot study is designed to determine the effects of BLI-1300 ointment on perianal pain associated with active Perianal Crohn's Disease (PCD).</brief_summary>
	<brief_title>A Safety and Efficacy Study of BLI-1300 Ointment in Symptomatic Perianal Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>All subjects must give written informed consent. Male or female subjects, 18 years of age. Confirmed diagnosis of Crohn's Disease. Subject must have a 3 month documented history of perianal Crohn's Disease (PCD) and with clinical evidence of active PCD. Subject must have a Crohn's Disease Activity Index (CDAI) total score of â‰¤ 350 at Visit 2. Subjects must have a qualifying perianal pain score at Visits 1 and 2. Women of childbearing potential who are not using adequate contraception. Women who are pregnant or breastfeeding. Subjects on unstable regimens of Crohn's therapy (e.g. tumor necrosis factor (TNF) inhibitors, immunosuppressants, steroids). Subjects taking strong analgesics that could interfere with pain measurements. Subjects with a perianal abscess requiring incision and drainage. Subjects with anal stenosis. Subjects with fistulae outside the immediate perianal area. Subjects who have had abdominal surgery for Crohn's disease within the past 12 weeks. Subjects who have had significant anorectal surgery for Crohns disease within the past 8 weeks.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Crohn's disease</keyword>
	<keyword>perianal</keyword>
	<keyword>inflammatory bowel disease</keyword>
	<keyword>fistula</keyword>
</DOC>